SCHEMBL3633787

SCHEMBL3633787

NC1=NC(c2ccncc2)(c2cccc(-c3cccnc3F)c2)c2cccnc21

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.61
BACE2 Q9Y5Z0 13/20 0.61
CTSD P07339 13/20 0.61
KCNH2 Q12809 5/20 0.54
REN P00797 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557028 0.90 BACE1 (0.67) BACE1BACE2CTSDKCNH2REN
SCHEMBL3640265 0.87 BACE1 (0.65) BACE1BACE2CTSDKCNH2REN
SCHEMBL3780600 0.86 BACE1 (0.60) BACE1BACE2CTSDKCNH2
SCHEMBL2085144 0.85 BACE1 (0.59) BACE1BACE2CTSDKCNH2
SCHEMBL3636805 0.85 BACE1 (0.57) BACE1BACE2CTSDKCNH2
SCHEMBL3847650 0.84 BACE1 (0.63) BACE1BACE2CTSDKCNH2REN
Trifluoroacetic Acid SCHEMBL2084197 0.82 BACE1 (0.57) BACE1BACE2CTSDKCNH2REN
SCHEMBL3633227 0.82 BACE1 (0.58) BACE1BACE2CTSDKCNH2
SCHEMBL3636240 0.82 BACE1 (0.72) BACE1BACE2KCNH2
SCHEMBL3998492 0.81 BACE1 (0.55) BACE1BACE2CTSDKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324072-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2010-12-23 US claimed
EP-2155749-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS AstraZeneca AB (SE) 2010-02-24 EP claimed
US-7629356-B2 Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions ASTRAZENECA AB (SE) 2009-12-08 US claimed
US-20090233945-A9 NEW COMPOUNDS 834 ASTRAZENECA AB (SE) 2009-09-17 US claimed
WO-2009022961-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2009-02-19 WO claimed
US-20080287462-A1 NEW COMPOUNDS 834 ASTRAZENECA AB (SE) 2008-11-20 US claimed
US-20100324072-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2010-12-23 US disclosed
EP-2155749-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS AstraZeneca AB (SE) 2010-02-24 EP disclosed
US-7629356-B2 Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions ASTRAZENECA AB (SE) 2009-12-08 US disclosed
US-20090233945-A9 NEW COMPOUNDS 834 ASTRAZENECA AB (SE) 2009-09-17 US disclosed
WO-2009022961-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2009-02-19 WO disclosed
US-20080287462-A1 NEW COMPOUNDS 834 ASTRAZENECA AB (SE) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324072-A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS BACE1, BACE2, PSEN1 BACE1 1/4885BACE2 2/4885CTSD 44/4885
US-20090233945-A9 NEW COMPOUNDS 834 MAPT, PSEN1, PSEN2 BACE1 4/4885BACE2 17/4885CTSD 1386/4885
US-20080287462-A1 NEW COMPOUNDS 834 MAPT, PSEN1, PSEN2 BACE1 4/4885BACE2 17/4885CTSD 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.